Status:
COMPLETED
FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
Lead Sponsor:
University Medical Center Groningen
Conditions:
Epithelial Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
Estrogens are implicated in the development of ovarian cancer and estrogen receptors (ER) alpha and beta are present in 20-100% of ovarian cancer patients. For this reason, antihormonal therapy with a...
Detailed Description
Investigators will evaluate whether FES-PET can be used to visualize and quantify ER-expression in ovarian cancer. If these results are positive, this would warrant further exploration of FES-PET imag...
Eligibility Criteria
Inclusion
- Histological evidence or high clinical suspicion of epithelial ovarian cancer
- The presence of at least one measurable lesion (RECIST version 1.1).
- Histology or cytology can be obtained (may be ascites)
- Eastern Cooperative Oncology Group performance status 0-2.
- Postmenopausal status (defined as either \>45 years with amenorrhea \>12 months, or prior bilateral ovariectomy)
- No history of other ER-positive malignancies
- Signed written informed consent
- Able to comply with the protocol
Exclusion
- Use of estrogen receptor ligands, including tamoxifen, fulvestrant or estrogens, during the 5 weeks before entry into the study
- Life-expectancy ≤ 3 months
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01439490
Start Date
August 1 2011
End Date
February 1 2014
Last Update
May 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Groningen
Groningen, Netherlands